Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled study
Which companies are included in the named provider set
Contact a doctor or poison control center immediately for guidance
If traditional diet and exercise methods have not yielded the results you desire, it may be time to consider this innovative treatment
[239] Illegal marketing of Evista [edit] In December 2005, Eli Lilly and Company pleaded guilty and paid $36 million in connection with the illegal promotion of Raloxifene (Evista), a medication typically used to prevent and treat osteoporosis in postmenopausal women
Employer Strategies On-Demand Webinars SmithRx Key Takeaways GLP-1s are highly effective for diabetes and obesity but surged demand and costs, use up ~587% and list prices near $1,000/mo, forcing prior auths and spiking employer drug spend